

# Nutrients for Eye-Related Diseases

Subjects: Ophthalmology

Submitted by:  Hip Seng

Yim

## Definition

The risk of macular degeneration can be reduced through the consumption of antioxidant-rich foods, supplements, and nutraceutical formulas. This study focuses on the antioxidants, vitamins, and minerals that have been reported for reducing the risk of macular degeneration and other eye-related diseases. Antioxidants including anthocyanins, carotenoids, flavonoids, and vitamins have been shown to reduce the risk of eye-related diseases. Anthocyanins extracted from berries are powerful antioxidants. Cyanidin, delphinidin, malvidin, pelargonidin, peonidin, and petunidin are anthocyanin aglycones detected in berries, currants, and other colored fruits and vegetables.  $\beta$ -Carotene, as well as xanthophyll lutein and zeaxanthin, have been reported to reduce the risk of macular degeneration. Flavonoids from plants help in the prevention of eye-related diseases through anti-inflammatory mechanisms. A combination of these antioxidants, vitamins, and minerals possess a synergistic effect on the prevention or risk reduction of macular degeneration. Formulas have been developed as dietary supplements to cater to the high demand from consumers and patients with eye problems.

---

## 1. Introduction

In recent years, several clinical trials and epidemiological studies have been conducted to evaluate the role of nutrients to improve or prevent visual loss in the elderly <sup>[1][2][3][4]</sup>. Many of these nutrients are strong antioxidants. Among the causes of visual loss worldwide, age-related macular degeneration (AMD) is the second most common cause of blindness after cataract in all regions, accounting for 15.4% (Western Europe) to 19.5% (Eastern Europe) of all blindness burden <sup>[5]</sup>. The rising prevalence of eye diseases causes a major social and economic burden to the country health care costs.


AMD is one of the age-related degenerative diseases, and it affects the macula which is responsible for high-acuity daylight vision in the central area of the retina <sup>[4]</sup>. The causes of AMD are multifactorial and include genetic predisposition, aging, and high oxidative stress <sup>[4]</sup>. Up to date, numerous studies suggest a positive association between the dietary micronutrients and decreases of progression in AMD and other eye-related diseases <sup>[1][2][4][6]</sup>. These studies have generated interest in micronutrients with antioxidant capabilities to prevent the oxidative damage involved in the development of degenerative eye diseases. Thus, micronutrients including antioxidants, vitamins, and minerals are attractive as promising strategies for preventative intervention.

## 2. Antioxidant Nutrients

### 2.1. Anthocyanins

Anthocyanins are the phytochemicals belonging to the phenolic group. These compounds have chemical structures similar to flavonoids, with a positive charge on the C-ring of the flavylum backbone <sup>[7]</sup>. Anthocyanins are red-purple pigments found in plants, they are strong antioxidants and have been reported to be the major components in the red, blue, and purple coloring of flowers, fruits, and vegetables <sup>[8]</sup>. Berries are colored fruits that have high anthocyanins content. Berries, such as blueberry, bilberry, blackcurrant, strawberry, and wolfberry (better known as 'goji berry'), are rich in anthocyanins. The berries also contain water-soluble flavonoid pigments—in part lending to the red, purple, and blue coloring of fruits and flowers—that act as potent antioxidants <sup>[9]</sup>. Among the berries, bilberry (*Vaccinium myrtillus*) extracts have been used as nutritional supplements <sup>[10][11]</sup>. Literature shows that bilberry extracts contained cyanidin and delphinidin as the major anthocyanin aglycones <sup>[12]</sup>. Among the six major, common anthocyanidins, cyanidin and delphinidin are abundantly found in most of the red to

purple colored plants. The chemical structures of cyanidin and delphinidin are shown in **Figure 1**.



**Figure 1.** Chemical structures of **(A)** cyanidin and **(B)** delphinidin.

Anthocyanins are known to have antioxidant and anti-inflammatory properties, which may reverse oxidative stress and possibly improve certain diseases. These compounds stabilize free radicals by its hydrogen donating ability [13]. Anthocyanins have been shown to promote regeneration and synthesis of rhodopsin [14] to protect retinal from overexposure to visible light [15] and exposure to irradiation [16], as well as to improve vision and increase the supply of blood to the retina [17]. This is also evidenced by an animal study which demonstrated that the subjects' eye, brain, and liver accumulated anthocyanins at week-4 of the blueberries-feed diet. The result showed that oral intakes of anthocyanins from natural sources (blueberries) provide the potential ocular protective benefits [18]. However, with the limitation of current laboratory level, one should be aware of its precise dosage and efficacy, and the potential toxicity and long-term side effects of the anthocyanins, especially when it comes from synthetic sources. The beneficial effects of anthocyanins in the prevention or risk reduction of AMD and other eye-related diseases are presented in **Table 1**. On the other hand, supplementation of 60 mg anthocyanins daily to the overweight and obese postmenopausal women (body mass index of 25–33 kg/m<sup>2</sup>) for eight months had no effect on macular pigment optical density [19].


**Table 1.** Protective effects of anthocyanins and carotenoids against age-related macular degeneration and eye-related complications.

Compounds	Study Design	Doses	Outcomes	Ref.
Anthocyanins				
Cyanidin 3-glucoside, cyanidin 3-rutinoside, delphinidin 3-glucoside, and delphinidin 3-rutinoside	In vitro bioassays: Rod outer segment and opsin membranes of frog	10–50 $\mu$ M	Positive outcomes: Cyanidin 3-glucoside and cyanidin 3-rutinoside stimulated regeneration of rhodopsin	[14]
Cyanidin 3-glucoside and delphinidin 3-glucoside	Cell culture: ARPE-19 cells (human retinal pigment epithelial cell line)	5 $\mu$ M	Positive outcome: Anthocyanins pre-treatment attenuated apoptosis of ARPE-19 cells induced by UVB irradiation.	[16]
Bilberry anthocyanin extract	In vivo study: Retinal degeneration model in pigmented rabbits (seven days)	250 and 500 mg/kg/day	Positive outcomes: Attenuated changes caused by light to Bax, Bcl-2, and caspase-3. Increased the levels of superoxide dismutase, glutathione peroxidase, catalase, and total antioxidant capacity. Decreased malondialdehyde level in the retinal cells. Inhibited light-induced elevation in the levels of pro-inflammatory cytokines and angiogenic parameters (IL-1 $\beta$ and VEGF).	[15]

Compounds	Study Design	Doses	Outcomes	Ref.
Anthocyanin supplement	Randomized, parallel study. Postmenopausal, one woman (eight months)	60 mg/day	Negative outcome (compared to baseline): No significant increase in macular pigment optical density	[19]
Carotenoids				
Lutein and zeaxanthin	Cell culture: ARPE-19 cells	5 µM	Positive outcome: Anthocyanins pre-treatment attenuated apoptosis of ARPE-19 cells induced by UVB irradiation.	[16]
Lutein and zeaxanthin	Prospective, randomized, double-blind, placebo-controlled human study (12 months)	10 mg/day lutein and 2 mg/day zeaxanthin	Positive outcomes: Significantly increased macular pigment optical density for treatment group compared to placebo. Significantly increased levels of serum lutein and zeaxanthin. Significantly improved chromatic contrast and photo stress recovery time for treatment group compared to placebo.	[20]
Zeaxanthin-containing spirulina (4–5 g)	Human feeding trials (45 days)	2.6–3.7 mg zeaxanthin	Positive outcome: Increased mean serum zeaxanthin concentration from 0.06 to 0.15 µmol/L.	[21]
Lutein, zeaxanthin, and meso-zeaxanthin in sunflower oil suspension	Double-blind, placebo-controlled, block-randomized human trial (12 months)	10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin	Positive outcomes: Significantly improved contrast sensitivity of the visual function after 12 months supplementation compared to baseline. Treatment group had significant increase in serum concentrations of the xanthophylls in retina and macular pigment optical density compared to placebo.	[22]
Lutein vs. α-tocopherol	Randomized, double-blind, placebo-controlled supplementation study (24 months)	12 mg lutein mixtures and 100 mg α-tocopherol	Positive outcomes: Significantly increased serum concentration of lutein. Increased visual performance (visual acuity and glare sensitivity) in lutein group only. No toxic effect found—no significant changes in hematological and biochemical profiles.	[23]
Oral total daily supplementation of antioxidants (mixture of β-carotene with other vitamins)	Randomized, placebo-controlled clinical trial (followed up for up to 10 years)	15 mg β-carotene	Positive primary outcome (compared to baseline): Reduced risk of visual acuity lost. Negative secondary outcomes: No significant differences for all the secondary outcomes between the treatment group and placebo.	[24]
Nutrient intake (β-carotene, β-cryptoxanthin, lutein, zeaxanthin, and lycopene)	Epidemiological study (Self-report data)	-	Positive outcome: Participants with the highest self-reported dietary intake of lutein and zeaxanthin were inversely associated with advanced age-related macular degeneration (AMD).	[25]
Total carotenoids (lutein/zeaxanthin, α-carotene, β-carotene, cryptoxanthin, and lycopene)	Eye Disease Case-Control Study	-	Positive outcome: Serum carotenoid level significantly associated with the risk of AMD	[26]
Xanthophyll supplement	Randomized, parallel study. Postmenopausal women (8 months)	6 mg lutein and 2 mg zeaxanthin daily)	Positive outcome: Dietary supplementation of lutein and zeaxanthin significantly increased the serum lutein and zeaxanthin levels. Negative outcome (compared to baseline): No significant increase in macular pigment optical density	[19]

## 2.2. Xanthophylls

Xanthophylls are the compounds belonging to the carotenoid group. Lutein and zeaxanthin are the two dietary carotenoid xanthophylls. The structures of these compounds are shown in **Figure 2**. Among the carotenoids, xanthophylls have no pro-vitamin A activity besides  $\beta$ -carotene. These compounds concentrated in the macula and are therefore known as a macular pigment, found in the human retina [27]. Lutein and zeaxanthin are the xanthophylls that act in the biological systems as (i) important structural molecules in cell membranes, (ii) short wavelength light filters, and (iii) keepers of the redox balance [28]. However, the human body is not able to synthesize both lutein and zeaxanthin. For that reason, it must be obtained from the diet. The foods that have lutein and zeaxanthin content are green leafy vegetables and fruits such as kale, avocado, and maize.



**Figure 2.** Chemical structures of (A) lutein, (B) zeaxanthin, and (C)  $\beta$ -carotene.

As shown in **Table 1**, xanthophylls including lutein and zeaxanthin, as well as  $\beta$ -carotene, are known to have protective effects against eye diseases and macular degeneration. Ma and Lin [29] also summarized the findings from several studies related to the protective effects of lutein and zeaxanthin on eye health, which included AMD, cataract, and retinitis pigmentosa. In this review, we summarized more recent studies related to serum concentrations of xanthophylls and the association with the risk of AMD and other eye-related complications.

Literature shows that the levels of lutein and zeaxanthin in plasma are associated with the decreased risk of macular disease such as AMD. A high intake of xanthophyll-containing foods has been attributed to the elevated levels of plasma lutein and zeaxanthin. As shown in the literature, short-term consumption of xanthophyll-rich foods, such as cooked egg yolk, vegetables, and spirulina, in the feeding group significantly increased plasma concentrations of the xanthophylls compared to the control group [21][23]. Therefore, the elevated levels of plasma lutein and zeaxanthin helped to prevent AMD in the elderly [30]. **Table 1** shows evidence of the protective effect of lutein and zeaxanthin against macular diseases [20][21][22][23][24]. However, there exists no report or recommendation for the optimal dose of these xanthophylls for treatment and prevention of macular degeneration and eye-related disease [31].

There are many factors affecting the degeneration of macular pigment. Lifestyle and dietary factors are important to be taken into consideration for prevention or slowing the progression of early AMD. Poor lifestyle choices such as physically inactive, poor diet, and smoking increase the risk of AMD. A previous study shows that inflammation of macular pigment among heavy smokers was higher than light or non-smokers [32]. The finding showed that serum concentrations of lutein and zeaxanthin are essential for smokers because they have lower macular pigment optical density than non-smokers. Dietary intakes of lutein and zeaxanthin also differ with age, sex, and ethnicity. Johnson et al. [33] suggested that intake of lutein is recommended to be higher than zeaxanthin among all age groups. There is still no recommended

daily intake for lutein and zeaxanthin, however, the randomized, double-blind, placebo-controlled human study showed health benefits at a daily intake of 10 mg of lutein and 2 mg of zeaxanthin [20].

Human intervention studies demonstrate that lutein and zeaxanthin supplementations improved visual performances, such as contrast sensitivity, glare tolerance, and photo stress recovery [20][29][34]. The result obtained from Age-Related Eye Disease Study 2 (AREDS 2) shows the beneficial effect of lutein and zeaxanthin supplementation related to AMD [35]. Based on scientific evidence (Table 1),  $\beta$ -carotene, lutein, and zeaxanthin are potent nutrients for reducing the risk of macular degeneration and eye-related diseases. On the contrary, one study reported that supplementation of 6 mg lutein and 2 mg zeaxanthin daily to postmenopausal women for eight months had no effect on the macular pigment optical density [17]. Owing to the fact that no specific doses have been prompted for the intakes of  $\beta$ -carotene, lutein, and zeaxanthin, policymakers and health care professionals should establish the dietary intake values for these carotenoids to encourage the public to increase the consumption of lutein-containing foods.

### 3. Vitamins

Vitamin A is closely related to its by-products, carotenoids, and plays several roles in the human body. Vitamin A intake and blood levels have also been examined for their roles in retinal health. Epidemiological data from the National Health and Nutrition Examination Survey (NHANES I) showed that those who consumed increased amounts of fruits and vegetables rich in vitamin A have a decreased risk for any stage of AMD [36]. The report summarized the protective effect of vitamin A with AMD.

Lately, a prospective population-based cohort also showed that long-term intake of fruits and vegetables that have provitamin A carotenoid further reduced risk of AMD [37]. On the contrary, several studies failed to show a significant association between increased dietary intake of vitamin A and reduced risk of macular degeneration (Table 2). Epidemiological studies showed no association between dietary intake of vitamin A and reduced risk of AMD [25][38]. With these conflicting results, more studies are needed to investigate the association between vitamin A and AMD.

**Table 2.** Positive and negative outcomes of vitamins and minerals against age-related macular degeneration and eye-related complications.

Compounds	Study Design	Doses	Outcomes	Ref.
Vitamins				
Mixture of vitamin C and vitamin E with provitamin A carotenoid	Randomized, placebo-controlled clinical trials (followed-up for up to 10 years)	Vitamin C (500 mg) and vitamin E (400 IU) daily	Positive primary outcomes (compared to baseline): Increase in nuclear, cortical, or posterior subcapsular opacity grades or cataract surgery. Moderate visual acuity lost ( $\geq 15$ letters). Negative secondary outcomes: No significant differences for all the secondary outcomes between the treatment group and placebo.	[21]
Provitamin A $\beta$ -carotene, vitamin C, and vitamin E	Age-Related Eye Disease Study	-	Positive outcomes: Increased intake of $\beta$ -carotene, vitamin C, and vitamin E associated with a reduced risk of neovascular AMD.	[39]
Vitamin A, vitamin C, and vitamin E	Systematic review and meta-analysis	-	Positive outcomes: Dietary intake of a mixture of vitamin A, vitamin C, and vitamin E had a larger effect on the reduction of AMD risk than the individual vitamin.	[40]

Compounds	Study Design	Doses	Outcomes	Ref.
Vitamin A, vitamin C, and vitamin E	Case-control study	-	Positive outcomes: Low dietary intake of vitamin C and vitamin E was associated with neovascular AMD. Negative outcome: Dietary vitamin A showed no association with neovascular AMD.	[41]
Vitamin E	Randomized controlled trial (four years)	500 IU daily	Negative outcomes: Failed to prevent the development and progression of AMD.	[42]
Vitamin E	Randomized placebo controlled 4-arm trial (follow-up of 5.6 ± 1.2 years)	400 IU daily (DL- $\alpha$ -tocopherol acetate)	Negative outcome: Vitamin supplementation showed no protective effect against cataracts among the participants (elderly men).	[43]
Vitamin A, vitamin C, and vitamin E	Multicenter eye disease case-control study (Epidemiological study)	-	Negative outcomes: Vitamins A, C, and E consumptions were not associated with the reduced risk of AMD.	[36]
Vitamin A (retinol), vitamin C (ascorbic acid), and vitamin E ( $\alpha$ -tocopherol)	POLA (Pathologies Oculaires Liées à l'Age) study	-	Negative outcomes: Plasma vitamin A and vitamin C showed no association with reduction in macular degeneration risk. Plasma vitamin E was negatively associated with early signs of AMD and late AMD.	[37]
Vitamin C	Cochrane Review	-	Negative outcomes: Vitamin C supplementation did not prevent any AMD or late AMD.	[44]
Vitamin C and vitamin E	Eye Disease Case-Control Study	-	Negative outcome: No statistically significant overall association was found between serum vitamin status and neovascular AMD.	[45]
<b>Minerals</b>				
Zinc	Case-control study	-	Positive outcome: Low dietary intake of zinc was associated with neovascular AMD.	[41]
Zinc	Randomized, placebo-controlled clinical trials (followed-up for up to 10 years)	Zinc oxide (80 mg daily)	Positive outcome: Significantly reduced the risk of developing advanced AMD.	[21]
Zinc	Randomized double-blinded, placebo-controlled trials (2 years intervention)	Zinc sulfate (200 mg daily)	Positive outcome: Significantly reduced visual loss in treatment group compared to placebo.	[46]
Zinc	Randomized, prospective, placebo-controlled clinical trial (three and six months intervention)	Zinc monocysteine (25 mg daily)	Positive outcomes: Significantly improved visual acuity and contrast sensitivity. Significantly shortened macular light flash recovery time both at three months and at six months.	[47]
Zinc	Randomized, double-blinded, placebo-controlled study (two years intervention)	Zinc sulfate (200 mg daily)	Positive outcome: Significantly increased serum zinc. Negative outcome: No significant improvement of eye conditions for patients with AMD.	[48]

Compounds	Study Design	Doses	Outcomes	Ref.
Selenium	Randomized, placebo-controlled, 4-arm trial (follow-up of 5.6 ± 1.2 years)	200 µg daily (from l-selenomethionine)	Negative outcome: Selenium supplementation did not show significant effect in reducing risk of cataracts among the participants (elderly men).	[43]

Vitamin C (ascorbic acid) is an effective antioxidant that protects proteins, lipids, carbohydrates, and nucleic acids from free radicals and reactive oxygen species (ROS) damage [39]. Several fruits and vegetables are good sources of vitamin C [3]. Due to vitamin C being a strong antioxidant, it is beneficial to the human eye and helps to prevent eye-related diseases. The beneficial effect of vitamin C against eye diseases is supported by a study conducted by SanGiovanni et al. [40]. The finding revealed a reduced likelihood of neovascular AMD (abnormal blood vessels growing underneath the retina) in subjects reporting high intakes of  $\beta$ -carotene, vitamin C, and vitamin E. In addition, the results obtained from a meta-analysis also showed that the pooled odds ratio of vitamin C supplements was 1.11 (0.84 to 1.46), in reference to early AMD [26]. On the other hand, Christen et al. [49] reported that users of vitamin C as a dietary supplement had a higher relative risk (1.03) of exudative macular degeneration than the users of vitamin E and multivitamin supplements (relative risk of  $\leq 0.9$ ) but it was not statistically significant. However, the enhancement of AMD by vitamin C supplementation is not related to the patients' genotype [50].

A recent Cochrane analysis conducted by Evans and Lawrenson [44] showed the controversial result that there was no significant association between vitamin C and primary prevention of AMD. The result was similar to the report published by the Eye Disease Case-Control Study Group [45] and Delcourt et al. [37], which showed no significant association between vitamin C intake and AMD. The no association between dietary vitamin C intake and reduced risk of AMD is further supported by Seddon et al. [36]. Another subsequent study showed no significant effects for vitamin C supplementation between the treatment group and placebo during the 10-year follow-up study [23]. On the whole, evidence from these studies shows no consistent relationship between dietary vitamin C intake and reduced risk for AMD. Therefore, further investigation is needed to be performed at a larger scale.

Vitamin E exists in four common forms in nature, namely,  $\alpha$ -tocopherol,  $\beta$ -tocopherol,  $\delta$ -tocopherol, and  $\gamma$ -tocopherol. It is an essential micronutrient and efficient antioxidant that scavenges free radicals. Deprivation of vitamin E could lead to lipofuscin accumulation [51], retinal damage [52], and loss of photoreceptors [53]. Due to vitamin E being a fat-soluble vitamin, it plays an important role in fatty acid metabolism. Vitamin E is involved in the desaturation of PUFAs via the microsomal electron transport chain [54]. In the human body,  $\alpha$ -tocopherol has been shown to be the most abundant in both plasma and retinal tissue [55][56]. Thus, studies suggested that increased dietary levels of vitamin E have been correlated with increased concentrations in the retina, and epidemiologic studies also suggest a beneficial effect of vitamin E for fighting the progression of AMD [57].

On the other hand, supplementation of vitamin E as high as 500 IU daily in a randomized controlled trial did not show a positive outcome in preventing the development and progression of AMD [42]. Some other previous studies also reported that supplementation of vitamin E individually, or with a combination of vitamins A and C, did not significantly reduce the risk of AMD (Table 2), however, subjects with the high levels of plasma carotenoids had significantly lower risk than the others [58]. Back in the 90s, the Pathologies Oculaires Liées à l'Age (POLA) study in France also reported no significant association between vitamin E intake and AMD [37]. On top of AMD, vitamin E supplementation (400 IU) showed no protective effect against cataract in older subjects [43]. Based on past studies, a high dosage of vitamin E supplementation may not necessarily benefit eye health. However, the antioxidative protective effect of vitamin E could not be easily ruled out. More large-scale studies need to be carried out to ascertain its effect on preventing AMD in humans.

## 4. Minerals

Zinc is a co-factor of many metabolically active enzymes within the eye and essential for many physiological processes including immunity, reproduction, and neuronal development [59][60]. Zinc is found in ocular tissue, particularly the retina [61], which is the reason that zinc supplementation may aid retinal health. A moderate amount of zinc supplementation helps to protect the retina—this is because zinc toxicity may occur at a higher level of zinc intake. Also, the elderly may have an increased risk of vision loss from AMD due to their higher risk of zinc deficiency.

Aoki et al. [41] reported that a high dose of zinc (80 mg) alone, which obtained through supplementation, reduced the risk of progression of neovascular AMD in the AREDS study. Dietary self-administration of zinc (200 mg) daily for up to 24 months had also proven to significantly reduce the visual loss compared to the placebo group [46]. A randomized, controlled clinical trial by Newsome evaluating a novel zinc, monocyteine, for the treatment and prevention of AMD showed significant improvements in visual acuity and contrast sensitivity, as well as a shortened macular light flash recovery time, in the treatment group at the third and sixth months of the trials compared to the placebo group [47].

On the contrary, the AREDS [62] showed that dietary intake of zinc had no significant differences for all the secondary outcomes between the treatment group and placebo. Another study also reported negative findings for zinc versus AMD [48]. According to the systematic review conducted by Vishwanathan et al. [63], the authors stated that zinc intake for the prevention of AMD was inconclusive due to the inconsistency of the findings reported by the cohort studies. They concluded that zinc treatment might be effective in preventing progression to advanced AMD. The review also concluded that zinc supplementation alone might not be sufficient to produce clinically significant changes in visual acuity. In addition to these findings, Assel et al. [64] reported that none of the evidence to support the reduced risk of AMD by zinc supplementation was related to patients' genotype. Klein and co-workers [50] reported, however, that the CC genotype of the patients could be a factor for the ineffectiveness of zinc supplementation in reducing the risk of AMD.

Selenium is well-known as an antioxidative agent, it is a trace element found in several enzymes of the human body. In the past years, a few studies have been focused on the effect of selenium in reducing the risk of AMD. Selenium-dependent glutathione peroxidase plays an important role in the protection against oxidative damage to membrane lipids [54][65]. Glutathione peroxidase functions as a mediator to reduce hydrogen peroxide and other possible hydroperoxides that present inside the cell. It is also hypothesized to be able to protect the macula against oxidative damage. However, these results have not been convincing and were inconclusive [45][66].

A low intake of dietary selenium is known to cause a reduction of total polyunsaturated fatty acids (PUFAs) in the retinal pigment epithelium and retinal rod outer segments of laboratory animals [67]. The fact is that selenium, together with vitamin E, is associated with fatty acid metabolism [54]. Due to the lack of case-control studies, the protective role of selenium and its enzymes in AMD remains unclear. Further studies warrant the efficacy of selenium for eye protection and the prevention of AMD and eye-related complications.

## References

1. Chew, E.Y. Nutrition effects on ocular diseases in the aging eye. *Investig. Ophthalmol. Vis. Sci.* 2013, 54, ORSF42-ORSF47.
2. Schleicher, M.; Weikel, K.; Garber, C.; Taylor, A. Diminishing risk for age-related macular degeneration with nutrition: A current view. *Nutrients* 2013, 5, 2405-2456.
3. Andreatta, W.; El-Sherbiny, S. Evidence-based nutritional advice for patients affected by age-related macular degeneration. *Ophthalmologica* 2014, 231, 185-190.
4. Gorusupudi, A.; Nelson, K.; Bernstein, P.S. The Age-Related Eye Disease 2 Study: Micronutrients in the treatment of macular degeneration. *Adv. Nutr.* 2017, 8, 40-53.



5. Bourne, R.R.; Jonas, J.B.; Bron, A.M.; Cicinelli, M.V.; Das, A.; Flaxman, S.R.; Friedman, D.S.; Keeffe, J.E.; Kempen, J.H.; Leasher, J.; et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. *Br. J. Ophthalmol.* 2018, 102, 575–585.
6. Hogg, R.; Chakravarthy, U. AMD and micronutrient antioxidants. *Curr. Eye Res.* 2004, 29, 387–401.
7. Khoo, H.E.; Azlan, A.; Tang, S.T.; Lim, S.M. Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. *Food Nutr. Res.* 2017, 61, 1361779.
8. Khoo, H.E.; Chew, L.Y.; Ismail, A.; Azlan, A. Anthocyanins in purple colored fruits. In *Polyphenols: Chemistry, Dietary Sources and Health Benefits*; Sun, J., Prasad, K.N., Ismail, A., Yang, B., You, X., Li, L., Eds.; Nova Science Publisher: New York, NY, USA, 2012; pp. 133–152. ISBN 978-1-62081-809-1.
9. Sin, H.P.; Liu, D.T.; Lam, D.S. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. *Acta Ophthalmol.* 2013, 91, 6–11.
10. Madhavi, D.; Bomser, J.; Smith, M.; Singletary, K. Isolation of bioactive constituents from *Vaccinium myrtillus* (bilberry) fruits and cell cultures. *Plant Sci.* 1998, 131, 95–103.
11. Jang, Y.P.; Zhou, J.; Nakanishi, K.; Sparrow, J.R. Anthocyanins protect against A2E photooxidation and membrane permeabilization in retinal pigment epithelial cells. *Photochem. Photobiol.* 2005, 81, 529–536.
12. Müller, D.; Schantz, M.; Richling, E. High performance liquid chromatography analysis of anthocyanins in bilberries (*Vaccinium myrtillus* L.), blueberries (*Vaccinium corymbosum* L.), and corresponding juices. *J. Food Sci.* 2012, 77, C340–C345.
13. Duan, X.; Jiang, Y.; Su, X.; Zhang, Z.; Shi, J. Antioxidant properties of anthocyanins extracted from litchi (*Litchi chinensis* Sonn.) fruit pericarp tissues in relation to their role in the pericarp browning. *Food Chem.* 2007, 101, 1365–1371.
14. Matsumoto, H.; Nakamura, Y.; Tachibanaki, S.; Kawamura, S.; Hirayama, M. Stimulatory effect of cyanidin 3-glycosides on the regeneration of rhodopsin. *J. Agric. Food Chem.* 2003, 51, 3560–3563.
15. Wang, Y.; Zhao, L.; Lu, F.; Yang, X.; Deng, Q.; Ji, B.; Huang, F. Retinoprotective effects of bilberry anthocyanins via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms in a visible light-induced retinal degeneration model in pigmented rabbits. *Molecules* 2015, 20, 22395–22410.
16. Silván, J.M.; Reguero, M.; de Pascual-Teresa, S. A protective effect of anthocyanins and xanthophylls on UVB-induced damage in retinal pigment epithelial cells. *Food Funct.* 2016, 7, 1067–1076.
17. Ghosh, D.; Konishi, T. Anthocyanins and anthocyanin-rich extracts: Role in diabetes and eye function. *Asia Pac. J. Clin. Nutr.* 2007, 16, 200–208.
18. Kalt, W.; Blumberg, J.B.; McDonald, J.E.; Vinqvist-Tymchuk, M.R.; Fillmore, S.A.; Graf, B.A.; O’Leary, J.M.; Milbury, P.E. Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. *J. Agric. Food Chem.* 2008, 56, 705–712.
19. Olmedilla-Alonso, B.; Estévez-Santiago, R.; Silván, J.M.; Sánchez-Prieto, M.; de Pascual-Teresa, S. Effect of long-term xanthophyll and anthocyanin supplementation on lutein and zeaxanthin serum concentrations and macular pigment optical density in postmenopausal women. *Nutrients* 2018, 10, 959.
20. Hammond, B.R.; Fletcher, L.M.; Roos, F.; Wittwer, J.; Schalch, W. A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast. *Investig. Ophthalmol. Vis. Sci.* 2014, 55, 8583–8589.
21. Yu, B.; Wang, J.; Suter, P.M.; Russell, R.M.; Grusak, M.A.; Wang, Y.; Yin, S.; Tang, G. Spirulina is an effective dietary source of zeaxanthin to humans. *Br. J. Nutr.* 2012, 108, 611–619. [Green Version]
22. Nolan, J.M.; Power, R.; Stringham, J.; Dennison, J.; Stack, J.; Kelly, D.; Moran, R.; Akuffo, K.O.; Corcoran, L.; Beatty, S. Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: Central Retinal Enrichment Supplementation Trials–Report 1. *Investig. Ophthalmol. Vis. Sci.* 2016, 57, 3429–3439.
23. Olmedilla, B.; Granado, F.; Blanco, I.; Vaquero, M. Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: A 2-y doubleblind, placebo-controlled pilot study. *Nutrition* 2003, 19, 21–24.
24. Stringham, J.M.; Hammond, B.R. Macular pigment and visual performance under glare conditions. *Optom. Vis. Sci.* 2008, 85, 82–88.
25. Delcourt, C.; Cristol, J.-P.; Tessier, F.; Léger, C.L.; Descomps, B.; Papoz, L. Age-related macular degeneration and antioxidant status in the POLA study. *Arch. Ophthalmol.* 1999, 117, 1384–1390.
26. Chong, E.W.; Wong, T.Y.; Kreis, A.J.; Simpson, J.A.; Guymer, R.H. Dietary antioxidants and primary prevention of age related macular degeneration: Systematic review and meta-analysis. *BMJ* 2007, 335, 755.
27. Bernstein, P.S.; Li, B.; Vachali, P.P.; Gorusupudi, A.; Shyam, R.; Henriksen, B.S.; Nolan, J.M. Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. *Prog. Retin. Eye Res.* 2016, 50, 34–66.
28. Eggersdorfer, M.; Wyss, A. Carotenoids in human nutrition and health. *Arch. Biochem. Biophys.* 2018, 652, 18–26.
29. Ma, L.; Lin, X.M. Effects of lutein and zeaxanthin on aspects of eye health. *J. Sci. Food Agric.* 2010, 90, 2–12.
30. Krinsky, N.I.; Landrum, J.T.; Bone, R.A. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye.

Annu. Rev. Nutr. 2003, 23, 171-201.

31. Zhao, L.; Sweet, B.V. Lutein and zeaxanthin for macular degeneration. *Am. J. Health Syst. Pharm.* 2008, 65, 1232-1238.
32. Nolan, J.M.; Stack, J.; O' Donovan, O.; Loane, E.; Beatty, S. Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. *Exp. Eye Res.* 2007, 84, 61-74.
33. Johnson, E.J.; Maras, J.E.; Rasmussen, H.M.; Tucker, K.L. Intake of lutein and zeaxanthin differ with age, sex, and ethnicity. *J. Am. Diet. Assoc.* 2010, 110, 1357-1362.
34. Chung, H.Y.; Rasmussen, H.M.; Johnson, E.J. Lutein bioavailability is higher from lutein-enriched eggs than from supplements and spinach in men. *J. Nutr.* 2004, 134, 1887-1893.
35. Chew, E.Y.; Clemons, T.E.; SanGiovanni, J.P.; Danis, R.P.; Ferris, F.L.; Elman, M.J.; Antoszyk, A.N.; Ruby, A.J.; Orth, D.; Bressler, S.B.; et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 Report No. 3. *JAMA Ophthalmol.* 2014, 132, 142-149.
36. Goldberg, J.; Flowerdew, G.; Smith, E.; Brody, J.A.; Tso, M.O.M. Factors associated with age-related macular degeneration: An analysis of data from the First National Health and Nutrition Examination Survey. *Am. J. Epidemiol.* 1988, 128, 700-710.
37. De Koning-Backus, A.P.; Buitendijk, G.H.; Kieft-de Jong, J.C.; Colijn, J.M.; Hofman, A.; Vingerling, J.R.; Haverkort, E.B.; Franco, O.H.; Klaver, C.C. Intake of vegetables, fruit, and fish is beneficial for Age-related Macular Degeneration. *Am. J. Ophthalmol.* 2019, 198, 70-79.
38. Seddon, J.M.; Ajani, U.A.; Sperduto, R.D.; Hiller, R.; Blair, N.; Burton, T.C.; Farber, M.D.; Gragoudas, E.S.; Haller, J.; Miller, D.T.; et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. *JAMA* 1994, 272, 1413-1420.
39. Zampatti, S.; Ricci, F.; Cusumano, A.; Marsella, L.T.; Novelli, G.; Giardina, E. Review of nutrient actions on age-related macular degeneration. *Nutr. Res.* 2014, 34, 95-105. [Green Version]
40. SanGiovanni, J.P.; Chew, E.Y.; Clemons, T.E.; Ferris, F.L., II; Gensler, G.; Lindblad, A.S.; Milton, R.C.; Seddon, J.M.; Sperduto, R.D. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. *Arch Ophthalmol.* 2007, 125, 1225-1232.
41. Aoki, A.; Inoue, M.; Nguyen, E.; Obata, R.; Kadonosono, K.; Shinkai, S.; Hashimoto, H.; Sasaki, S.; Yanagi, Y. Dietary n-3 fatty acid,  $\alpha$ -tocopherol, zinc, vitamin D, vitamin C, and  $\beta$ -carotene are associated with age-related macular degeneration in Japan. *Sci. Rep.* 2016, 6, 20723.
42. Taylor, H.R.; Tikellis, G.; Robman, L.D.; McCarty, C.A.; McNeil, J.J. Vitamin E supplementation and macular degeneration: Randomised controlled trial. *Br. Med. J.* 2002, 325, 11.
43. Christen, W.G.; Glynn, R.J.; Gaziano, J.M.; Darke, A.K.; Crowley, J.J.; Goodman, P.J.; Lippman, S.M.; Lad, T.E.; Bearden, J.D.; Goodman, G.E.; et al. Age-related cataract in men in the selenium and vitamin E cancer prevention trial eye endpoints study: A randomized clinical trial. *JAMA Ophthalmol.* 2015, 133, 17-24.
44. Evans, J.R.; Lawrenson, J.G. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. *Cochrane Database Syst. Rev.* 2017, 7, CD000253.
45. Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. *Arch. Ophthalmol.* 1993, 111, 104-109.
46. Newsome, D.A.; Swartz, M.; Leone, N.C.; Elston, R.C.; Miller, E. Oral zinc in macular degeneration. *Arch. Ophthalmol.* 1988, 106, 192-198.
47. Newsome, D.A. A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. *Curr. Eye Res.* 2008, 33, 591-598.
48. Stur, M.; Tittl, M.; Reitner, A.; Meisinger, V. Oral zinc and the second eye in age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 1996, 37, 1225-1235.
49. Christen, W.G.; Ajani, U.A.; Glynn, R.J.; Manson, J.E.; Schaumberg, D.A.; Chew, E.C.; Buring, J.E.; Hennekens, C.H. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. *Am. J. Epidemiol.* 1999, 149, 476-484.
50. Klein, M.L.; Francis, P.J.; Rosner, B.; Reynolds, R.; Hamon, S.C.; Schultz, D.W.; Ott, J.; Seddon, J.M. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. *Ophthalmology* 2008, 115, 1019-1025.
51. Robison, W.G.; Kuwabara, T.; Bieri, J.G. The roles of vitamin E and unsaturated fatty acids in the visual process. *Retina* 1982, 2, 263-281.
52. Tanito, M.; Yoshida, Y.; Kaidzu, S.; Chen, Z.-H.; Cynshi, O.; Jishage, K.-I.; Niki, E.; Ohira, A. Acceleration of age-related changes in the retina in  $\alpha$ -tocopherol transfer protein null mice fed a vitamin E-deficient diet. *Investig. Ophthalmol. Vis. Sci.* 2007, 48, 396-404.
53. Katz, M.L.; Eldred, G.E. Failure of vitamin E to protect the retina against damage resulting from bright cyclic light exposure. *Investig. Ophthalmol. Vis. Sci.* 1989, 30, 29-36.
54. Infante, J.P. Vitamin E and selenium participation in fatty acid desaturation. A proposal for an enzymatic function of these nutrients. *Mol. Cell. Biochem.* 1986, 69, 93-108.

55. Handelman, G.J.; Machlin, L.J.; Fitch, K.; Weiter, J.J.; Dratz, E.A. Oral  $\alpha$ -tocopherol supplements decrease plasma  $\gamma$ -tocopherol levels in humans. *J. Nutr.* 1985, 115, 807–813.
56. Alvarez, R.; Liou, F.; Fong, S. Levels of alpha-, and gamma-tocopherol in human eyes: Evaluation of the possible role of IRBP in intraocular alpha-tocopherol transport. *Am. J. Clin. Nutr.* 1987, 46, 481–487.
57. Belda, J.I.; Romá, J.; Vilela, C.; Puertas, F.J.; Díaz-Llopis, M.; Bosch-Morell, F.; Romero, F.J. Serum vitamin E levels negatively correlate with severity of age-related macular degeneration. *Mech. Ageing Dev.* 1999, 107, 159–164.
58. Thurnham, D.I. Macular zeaxanthins and lutein—A review of dietary sources and bioavailability and some relationships with macular pigment optical density and age-related macular disease. *Nutr. Res. Rev.* 2007, 20, 163–179.
59. Grahn, B.H.; Paterson, P.G.; Gottschall-Pass, K.T.; Zhang, Z. Zinc and the eye. *J. Am. Coll. Nutr.* 2001, 20, 106–118.
60. King, J.C. Zinc: An essential but elusive nutrient. *Am. J. Clin. Nutr.* 2011, 94, 679S–684S.
61. Ugarte, M.; Osborne, N.N. Zinc in the retina. *Prog. Neurobiol.* 2001, 64, 219–249.
62. Age-Related Eye Disease Study Research Group (AREDS). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. *Arch. Ophthalmol.* 2001, 119, 1417–1436.
63. Vishwanathan, R.; Chung, M.; Johnson, E.J. A systematic review on zinc for the prevention and treatment of age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.* 2013, 54, 3985–3998.
64. Assel, M.J.; Li, F.; Wang, Y.; Allen, A.S.; Baggerly, K.A.; Vickers, A.J. Genetic polymorphisms of CFH and ARMS2 do not predict response to antioxidants and zinc in patients with age-related macular degeneration: Independent statistical evaluations of data from the Age-Related Eye Disease Study. *Ophthalmol.* 2018, 125, 391–397.
65. Ursini, F.; Bindoli, A. The role of selenium peroxidases in the protection against oxidative damage of membranes. *Chem. Phys. Lipids* 1987, 44, 255–276.
66. Tsang, N.C.; Penfold, P.L.; Snitch, P.J.; Billson, F. Serum levels of antioxidants and age-related macular degeneration. *Doc. Ophthalmol.* 1992, 81, 387–400.
67. Farnsworth, C.C.; Stone, W.L.; Dratz, E.A. Effects of vitamin E and selenium deficiency on the fatty acid composition of rat retinal tissues. *Biochim. Biophys. Acta* 1979, 552, 281–293.

---

## Keywords

anthocyanin; dietary supplement; lutein; mineral; vitamin; zeaxanthin

---